Income statement
CAD
Annual
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 35K | 672K | 268K | 106K | 136K |
| Gross Profit | -29K | 622K | 199K | 52K | 136K |
| Operating Income | -2M | -4M | -2M | -4M | -4M |
| EBITDA | -2M | -4M | -2M | -4M | 0 |
| Net Income | -3M | -4M | -2M | -4M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.0051
+0.00% today
1Y Change
+15.91%
Window
Jun 23, 2025 → Jun 11, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Sirona Biochem Corp. (SRBCF) is a Healthcare stock with listed on OTC. The stock last traded around $0.01 and up 15.9% across the available one-year price window (Jun 23, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of -94.8%, EPS growth of +31.8%, a dividend yield of 0.0%. What stands out right now is revenue -94.8%, EPS +31.8%, free cash flow +19.3% with operating margin -6917.6% and ROIC 1259.2%. Valuation already assumes a fairly strong business story at price/sales 63.9. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SRBCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SRBCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SRBCF Max Drawdown
-99.53%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SRBCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$135.7K
+28.4% YoY
FY Net Income
-$4.5M
-10.1% YoY
Free Cash Flow
-$3.6M
-64.9% YoY
Revenue Growth
-94.8%
EPS Growth
+31.8%
Gross Margin
-82.7%
Net Margin
-7312.4%
Income statement
CAD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 35K | 672K | 268K | 106K | 136K |
| Gross Profit | -29K | 622K | 199K | 52K | 136K |
| Operating Income | -2M | -4M | -2M | -4M | -4M |
| EBITDA | -2M | -4M | -2M | -4M | 0 |
| Net Income | -3M | -4M | -2M | -4M | -5M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Cash & Equivalents | 571K | 422K | 778K | 2M | 4M |
| Total Assets | 1M | 1M | 1M | 2M | 4M |
| Total Liabilities | 4M | 1M | 1M | 2M | 2M |
| Shareholder Equity | -3M | 215K | -97K | 47K | 2M |
| Total Debt | 2M | 470K | 851K | 1M | 2M |
| Net Debt | 2M | 49K | 73K | -294K | -2M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
4M
-68.5% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
4M
-64.9% YoY
Key ratios
Gross Margin
-82.7%
Operating Margin
-6917.6%
Net Margin
-7312.4%
ROE
221.5%
Debt / Equity
-0.87x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.